FDA-approved1,2Evidence: Large human trialsHeart and blood vessels

Bivalirudin1

Also called Angiomax2

Key takeaway

Bivalirudin is a synthetic peptide of 20 amino acids that directly blocks thrombin, the enzyme that forms blood clots. It was first approved in the United States as Angiomax.1,2 Its U.S. label covers use as an anticoagulant during percutaneous coronary intervention (PCI), the procedure that opens narrowed heart arteries, including in people with heparin-induced thrombocytopenia.1 In the Bivalirudin Angioplasty Trial of 4,312 people, it was not shown to be better than heparin at preventing death, heart attack or vessel closure; event rates were similar. The label warns that it increases bleeding risk.1

Bivalirudin at a glance

What it isA synthetic 20-amino-acid peptide that binds both the active site and a second binding site of thrombin, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Angiomax with an original approval date of December 15, 2000. The cited label has no boxed warning.1,2
Human evidenceRandomized trials comparing it with heparin in people undergoing coronary procedures, and a single-arm study in 51 people with heparin-induced thrombocytopenia, described in the label.1
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is bivalirudin?

Bivalirudin is a synthetic peptide of 20 amino acids and a specific, reversible direct thrombin inhibitor, according to the label.1

Drugs@FDA lists the original application, Angiomax (NDA 020873), now held by Sandoz. Several other companies also hold approvals for bivalirudin.2

How does bivalirudin work?

The label states that bivalirudin binds both the catalytic site and the anion-binding exosite of thrombin, whether thrombin is circulating or bound in a clot.1

Thrombin turns fibrinogen into fibrin, the mesh of a clot, and activates other clotting factors, so blocking it slows clot formation, according to the label.1

What do human studies show?

In the Bivalirudin Angioplasty Trial, 4,312 people with unstable angina undergoing angioplasty were randomized to bivalirudin or heparin. The label states the studies did not show bivalirudin to be superior for death, heart attack, vessel closure or worsening needing further procedures, and that these events occurred at similar rates.1

In the same trials, 3.7% of people given bivalirudin had major bleeding events, according to the label.1

The label also describes a single-arm study of 51 people with heparin-induced thrombocytopenia who underwent PCI with bivalirudin.1

What the evidence base contains

  • Large randomized human trial The Bivalirudin Angioplasty Trial (BAT): randomized studies in 4,312 people with unstable angina undergoing coronary angioplasty, comparing bivalirudin with heparin, described in the label.1
  • Small, short, or incompletely reported human study A single-arm, open-label study in 51 people with heparin-induced thrombocytopenia undergoing PCI, described in the label.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is bivalirudin FDA-approved?

Yes. Drugs@FDA lists Angiomax, application NDA 020873, with an original approval date of December 15, 2000.2

The bivalirudin label cited here (DailyMed SPL version 5, published July 29, 2026) states that it is indicated as an anticoagulant in patients undergoing PCI, including patients with heparin-induced thrombocytopenia or heparin-induced thrombocytopenia and thrombosis syndrome.1

The label has no boxed warning. It is contraindicated in active major bleeding, and its warnings state that bivalirudin increases the risk of bleeding.1

Timeline

  1. FDA approves Angiomax, according to Drugs@FDA.2
  2. DailyMed publishes the bivalirudin label version cited on this page.1

What is still unknown?

The label states that the clinical relevance of its laboratory clotting-test effects is unknown.1

How it compares with current alternatives beyond heparin, since the trials described in the label compared it mainly with heparin.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Bivalirudin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Bivalirudin are a bounded selection, not every registration or paper about Bivalirudin. For the years before Bivalirudin was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Bivalirudin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Bivalirudin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Angiomax and generics as an anticoagulant during coronary procedures. Randomized trials of 4,312 people described in the label found event rates similar to heparin. The label warns that bivalirudin increases the risk of bleeding.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Bivalirudin?

FDA-approved as Angiomax and generics as an anticoagulant during coronary procedures. Randomized trials of 4,312 people described in the label found event rates similar to heparin. The label warns that bivalirudin increases the risk of bleeding.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
19
Drugs@FDA applications
14

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 15, 2026

    Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review.↗Source date November 9, 2026
  2. Literature metadata · added November 15, 2026

    Bivalirudin versus heparin in adult and pediatric patients with extracorporeal membrane oxygenation therapy: A systematic review and meta-analysis.↗Source date November 9, 2026
  3. Literature metadata · added November 15, 2026

    Bivalirudin vs. heparin in paediatric and adult patients on extracorporeal membrane oxygenation: A meta-analysis.↗Source date November 9, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Bivalirudin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

78Selected dated records
80Connected citations
19Populated source years1998–2026
3/4Record lanes present

Registered human studies

Trial composition

28 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.

PhasesPhase 4 10Phase 3 9Not applicable 5Phase 2 3Phase 1 1
Status at observationCompleted 22Recruiting 6Active, not recruiting 1Not yet recruiting 1

A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”

PubMed bibliography

Publication composition

30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 29Meta-Analysis 11Review 10Systematic Review 9Comparative Study 7Randomized Controlled Trial 7Research Support, Non-U.S. Gov't 5Multicenter Study 2Clinical Trial, Phase I 1Letter 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
14
FDA Federal Register documents
4
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
78

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 78 dated records

Research hub

Explore the Bivalirudin evidence record

Open all 78 records →
78Dated records
3Evidence types
78Cited public sources
19Source years

Change ledger

Recently changed for Bivalirudin

Open all 78 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00043940

PeptideScanner retained ClinicalTrials.gov record NCT00043940 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-09-16, and PeptideScanner's reviewed identity mapping was bivalirudin.

PeptideScanner change date
November 15, 2026
Cited source date
September 16, 2011
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00073580

PeptideScanner retained ClinicalTrials.gov record NCT00073580 at 2026-11-15T21:58:19.888Z. Its registry update date was 2018-11-30, and PeptideScanner's reviewed identity mapping was bivalirudin.

PeptideScanner change date
November 15, 2026
Cited source date
November 30, 2018
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00073593

PeptideScanner retained ClinicalTrials.gov record NCT00073593 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-11-10, and PeptideScanner's reviewed identity mapping was bivalirudin.

PeptideScanner change date
November 15, 2026
Cited source date
November 10, 2011
Evidence lane
Clinical trials

Official-source collections

Source records for Bivalirudin

Open the full research atlas →
PubMed30

30 with attributed title, venue, publication-date, and type metadata.

  1. Bivalirudin Versus Heparin and Protamine in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis.Annals of cardiac anaesthesia · 2026 10 12
  2. Bivalirudin as an Alternative to Heparin in Pediatric Cardiac Procedures: Evidence, Challenges, and Future Directions.Sage open pediatrics · 2026 08 13
  3. BMI differences on anticoagulation with bivalirudin vs. heparin during primary PCI: a BRIGHT-4 subanalysis.BMC medicine · 2025 09 30
Explore all selected literature →
ClinicalTrials.gov30

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT03537586Registry update November 4, 2026 · current at observation
  2. NCT04278404Registry update August 21, 2026 · current at observation
  3. NCT06080074Registry update August 10, 2026 · current at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA14

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. ANDA213078Full FDA chronology · original submission status AP 2021-05-28
  2. ANDA210031Full FDA chronology · original submission status AP 2019-10-23
  3. NDA211215Full FDA chronology · original submission status AP 2019-07-25
  4. ANDA205962Full FDA chronology · original submission status AP 2018-07-27
  5. ANDA091602Full FDA chronology · original submission status AP 2018-07-16
Explore all selected FDA applications →Explore 0 dated submissions and 0 documents for Bivalirudin →

Evidence types

Coverage by source year

Selected records span September 23, 1998 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 78

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review.↗

    PubMed lists PMID 29461391 in Anesthesia and analgesia as Journal Article, Review, with publication-date metadata of 2019-01 (month precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Bivalirudin versus heparin in adult and pediatric patients with extracorporeal membrane oxygenation therapy: A systematic review and meta-analysis.↗

    PubMed lists PMID 35065202 in Pharmacological research as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2022-01-20 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Bivalirudin vs. heparin in paediatric and adult patients on extracorporeal membrane oxygenation: A meta-analysis.↗

    PubMed lists PMID 35098565 in British journal of clinical pharmacology as Journal Article, Meta-Analysis, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-02-14 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation.↗

    PubMed lists PMID 35616224 in Perfusion as Journal Article, Meta-Analysis, with publication-date metadata of 2022-05-26 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Heparin Versus Bivalirudin for Anticoagulation in Adult Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis.↗

    PubMed lists PMID 36355803 in ASAIO journal (American Society for Artificial Internal Organs : 1992) as Meta-Analysis, Systematic Review, Journal Article, with publication-date metadata of 2022-11-09 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Meta-Analysis Comparing Bivalirudin Versus. Unfractionated Heparin in Adult Patients With Extracorporeal Membrane Oxygenation.↗

    PubMed lists PMID 36449392 in Journal of pharmacy practice as Meta-Analysis, Journal Article, with publication-date metadata of 2022-11-30 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis.↗

    PubMed lists PMID 37865864 in Coronary artery disease as Meta-Analysis, Journal Article, with publication-date metadata of 2023-09-20 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Bivalirudin in Extracorporeal Membrane Oxygenation.↗

    PubMed lists PMID 39259286 in Journal of cardiovascular pharmacology as Journal Article, Review, with publication-date metadata of 2024-12-01 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation.↗

    PubMed lists PMID 39585174 in Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies as Journal Article, Randomized Controlled Trial, Comparative Study, with publication-date metadata of 2024-11-25 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Bivalirudin Versus Heparin and Protamine in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis.↗

    PubMed lists PMID 42862663 in Annals of cardiac anaesthesia as Journal Article, Systematic Review, Meta-Analysis, Comparative Study, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT03537586↗

    PeptideScanner retained ClinicalTrials.gov record NCT03537586 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was bivalirudin.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT04278404↗

    PeptideScanner retained ClinicalTrials.gov record NCT04278404 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was bivalirudin.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Bivalirudin for injection, powder, lyophilized, for solution (Sandoz Inc.) · SPL version 5 · published 2026-07-29 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: ANGIOMAX (bivalirudin), NDA 020873 · original approval December 15, 2000 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026